Sector Expert: Jason Napodano

BioNap Inc.

Image: Jason Napodano

Jason Napodano of BioNap Consulting formerly worked for Zacks Investment Research as the company's senior biotechnology analyst. Prior to his tenure at Zacks, Napodano spent three years on the buyside with Eastover Capital in Charlotte, N.C., where he focused on large-cap equities and specialized in healthcare, energy and technology. Prior to joining Eastover, Napodano worked as a research scientist for TechLab Inc., a biotechnology company focused on developing diagnostic kits and vaccines for infectious diseases. He also spent a year working in a lab at the Fralin Biotechnology Center, and a year working for a cancer researcher in Virginia. Napodano has a bachelor's degree in biochemistry from Virginia Tech and a master's degree in business administration and finance, with a concentration in securities analysis, from Wake Forest University. Napodano is also a Chartered Financial Analyst (CFA).



Recent Interviews

Time to Go Long on BrainStorm Cell Therapeutics? (1/16/17)
NurOwn Technology

Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics, including the science, the Phase 2 data and the potential valuation of the company developing adult stem cell-based therapies for neurodegenerative diseases.

Delving Deep into Immune Pharmaceuticals' Diverse Pipeline (5/4/16)
beakerswithfloaters.630

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer. The company has several active clinical programs, led by bertilimumab, a first-in-class, fully human IgG4 monoclonal antibody, which is currently in Phase 2 clinical trials for the treatment of inflammatory bowel disease and skin disorders. Immune Pharma also has a growing presence in immuno-oncology, with the goal to create a fully sustained oncology subsidiary in the near future. In this article for The Life Sciences Report, analyst Jason Napodano digs into the company's pipeline and investment potential.

Let Your Biotech Winners Ride into Orbit: Jason Napodano of BioNap Consulting (12/16/15)
goldpill630

Before starting his own firm in July, Jason Napodano spent more than 12 years at Zacks Investment Research producing highly detailed small-cap biotechnology research. Today, as owner and senior analyst at BioNap Consulting, Napodano is doing much the same, but with more flexibility. He follows dozens of companies and continues to perform diligence on new names with the single goal of finding multibaggers. One of his themes is to take a biotech basket-of-stocks approach, since he knows some names will fail but the winners will move upward with momentum. In this interview with The Life Sciences Report, Napodano discusses small-cap names with the potential to power portfolios to extraordinary levels.

Recent Quotes

"ATNM announced this week that they have initiated discussions with the European Medicines Agency on a clinical development program for Iomab-B in the EU."

— Jason Napodano, BioNap Inc. (10/28/16)
more >

"I encourage investors to take a look at ATNM because the stock is at a fantastic discount and you now have two drugs, Iomab-B and Actimab-A in Phase 3 and Phase 2 clinical trials."

— Jason Napodano, BioNap Inc. (9/30/16)
more >

"BOTA is well funded and has lots of clinical catalysts coming in 2016."

The Life Sciences Report Interview with Jason Napodano (12/16/15)
more >

"RNN has three very interesting, early-stage anticancer drugs, and a sound development program."

The Life Sciences Report Interview with Jason Napodano (12/16/15)
more >

"BCT is early stage right now, but I really like the science."

The Life Sciences Report Interview with Jason Napodano (12/16/15)
more >

"CANF had big potential in its clinical pipeline and an incredibly cheap valuation."

The Life Sciences Report Interview with Jason Napodano (12/16/15)
more >

"If results from RVX's Phase 3 program are positive, the stock could have a significant revaluation to much higher levels."

The Life Sciences Report Interview with Jason Napodano (7/8/15)
more >

"CYNA is now well funded, NASDAQ-listed and liquid; it isdefinitely among my better ideas as of today."

The Life Sciences Report Interview with Jason Napodano (7/8/15)
more >

more comments

"I think a large pharma company would be very interested in CTRV's FV-100."

The Life Sciences Report Interview with Jason Napodano (7/8/15)
more >

"BCLI has what looks to be a safe and potentially effective treatment for delaying disease progression in patients with ALS."

The Life Sciences Report Interview with Jason Napodano (7/8/15)
more >

"Signs point to fundamental strength for CTH."

— Jason Napodano, Zacks Small-Cap Research (6/22/15)
more >

"For all indications, we estimate CANF will sign partnership agreements."

— Jason Napodano, Zacks Small-Cap Research (6/2/15)
more >

"Efficacy of CANF's CF101 in psoriasis is similar to Celgene's Otezla."

— Jason Napodano, Seeking Alpha (4/29/15)
more >

"RVX is addressing the major unmet medical need of cardiovascular management."

— Jason Napodano, Zacks Equity Research (4/20/15)
more >

"BCLI has a favorable risk/reward profile and tremendous upside for Nur-Own."

— Jason Napodano, Seeking Alpha (4/13/15)
more >

fewer comments


Due to permission requirements, not all quotes are shown.